SG Americas Securities LLC Purchases 152,170 Shares of Novo Nordisk A/S $NVO

SG Americas Securities LLC lifted its position in Novo Nordisk A/S (NYSE:NVO) by 6.4% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 2,535,346 shares of the company’s stock after purchasing an additional 152,170 shares during the period. SG Americas Securities LLC owned about 0.06% of Novo Nordisk A/S worth $128,998,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other large investors also recently modified their holdings of the company. Franklin Resources Inc. raised its holdings in Novo Nordisk A/S by 4,190.8% during the third quarter. Franklin Resources Inc. now owns 13,984,789 shares of the company’s stock valued at $776,016,000 after acquiring an additional 13,658,867 shares during the period. Capital International Investors boosted its stake in shares of Novo Nordisk A/S by 52.4% in the third quarter. Capital International Investors now owns 17,713,424 shares of the company’s stock worth $982,969,000 after acquiring an additional 6,092,192 shares during the period. Boston Partners purchased a new stake in shares of Novo Nordisk A/S during the third quarter worth about $310,199,000. Clear Street Group Inc. bought a new stake in Novo Nordisk A/S during the 3rd quarter valued at approximately $56,378,000. Finally, DAVENPORT & Co LLC raised its stake in Novo Nordisk A/S by 54.8% during the 3rd quarter. DAVENPORT & Co LLC now owns 2,642,498 shares of the company’s stock valued at $146,644,000 after purchasing an additional 935,468 shares during the period. Hedge funds and other institutional investors own 11.54% of the company’s stock.

Key Headlines Impacting Novo Nordisk A/S

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: FDA clears a higher-dose formulation of Wegovy, which can deepen Novo Nordisk’s obesity franchise and support sales/price power for its semaglutide lineup. FDA Clears NVO’s Higher Dose of Wegovy
• Positive Sentiment: Novo Nordisk launched a Phase 1 study of LX9851, an oral non‑incretin obesity candidate licensed from Lexicon, expanding the pipeline beyond injectable semaglutides and offering long‑term upside if oral assets succeed. Lexicon and Novo Nordisk Announce Phase 1
• Positive Sentiment: Ongoing share repurchase programme (part of up to DKK 15bn plan) supports EPS and signals management confidence, which can be a near‑term technical tailwind. Novo Nordisk A/S – share repurchase programme
• Neutral Sentiment: Analyst and valuation pieces are mixed: some highlight Novo’s entrenched market position and recent approvals, while others warn of slowing growth and competition—contributing to divergent investor views on valuation. Novo Nordisk Valuation Check As LX9851 Expands
• Negative Sentiment: Indian patent expiry has opened the floodgates: multiple Indian manufacturers launched low‑cost generics of Ozempic/Wegovy (semaglutide), cutting prices by ~70% locally and setting a precedent for aggressive generic competition in price‑sensitive markets. This raises long‑term pricing and volume risk outside core markets. Indian drugmakers flood market with cheaper versions
• Negative Sentiment: Multiple reports emphasize cheap generic launches in India and other local markets (coverage by CNBC, DrugStoreNews, Moby), underscoring immediate revenue pressure where patent protection has lapsed and the risk of parallel imports or international pricing pressure over time. India launching cheap weight-loss drugs

Novo Nordisk A/S Stock Performance

NYSE NVO opened at $36.81 on Tuesday. The company has a debt-to-equity ratio of 0.61, a current ratio of 0.80 and a quick ratio of 0.57. Novo Nordisk A/S has a 1-year low of $35.85 and a 1-year high of $81.44. The business has a 50 day simple moving average of $47.76 and a two-hundred day simple moving average of $50.93. The stock has a market capitalization of $164.36 billion, a PE ratio of 10.61 and a beta of 0.73.

Novo Nordisk A/S (NYSE:NVO) last issued its quarterly earnings data on Tuesday, February 3rd. The company reported $1.01 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.90 by $0.11. The business had revenue of $12.43 billion for the quarter, compared to analysts’ expectations of $11.97 billion. Novo Nordisk A/S had a return on equity of 68.91% and a net margin of 33.03%. On average, research analysts predict that Novo Nordisk A/S will post 3.84 EPS for the current fiscal year.

Novo Nordisk A/S Dividend Announcement

The firm also recently declared a dividend, which will be paid on Wednesday, April 8th. Investors of record on Monday, March 30th will be paid a dividend of $1.2751 per share. The ex-dividend date of this dividend is Monday, March 30th. This represents a yield of 541.0%. Novo Nordisk A/S’s dividend payout ratio is presently 52.74%.

Analyst Ratings Changes

NVO has been the subject of several recent analyst reports. Deutsche Bank Aktiengesellschaft downgraded Novo Nordisk A/S from a “buy” rating to a “hold” rating in a research note on Monday, February 23rd. Zacks Research raised shares of Novo Nordisk A/S from a “strong sell” rating to a “hold” rating in a report on Tuesday, March 10th. Kepler Capital Markets lowered shares of Novo Nordisk A/S from a “buy” rating to a “hold” rating in a research report on Tuesday, February 24th. HSBC reaffirmed a “hold” rating and set a $54.00 target price on shares of Novo Nordisk A/S in a research note on Wednesday, December 10th. Finally, Jefferies Financial Group upgraded shares of Novo Nordisk A/S from an “underperform” rating to a “hold” rating in a report on Thursday, February 12th. Four equities research analysts have rated the stock with a Buy rating, eighteen have given a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus price target of $65.56.

About Novo Nordisk A/S

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.